Predictors of Current CD4+ T-Cell Count Among Women of Reproductive Age on Antiretroviral Therapy in Public Hospitals, Southwest Ethiopia

References

• UNAIDS. Global HIV & AIDS statistics — 2020 fact sheet. 2020; Available from: https://www.unaids.org/en/resources/fact-sheet. Accessed November 6, 2020.
   Google Scholar
• AmfAR. Statistics: women and HIV/AIDS. 2020; Available from: https://www.amfar.org/about-hiv-and-aids/facts-and-stats/statistics–women-and-hiv-aids/. Accessed May 13, 2021.
   Google Scholar
• Charles M, Boyle B. Excess and access: the continuing controversy regarding HIV and health care in Africa. AIDS Read. 2002;12(7):288.
   Google Scholar
• UNAIDS. UNAIDS country director, Ethiopia - eligibility to apply limited; check additional information*; 2020; Available from: https://erecruit.unaids.org/public/hrd-cl-vac-view.asp?o_c=1000&jobinfo_uid_c=36610&vaclng=en. Accessed June 1, 2021.
   Google Scholar
• UNAIDS. Ethiopia | UNAIDS; 2020. Available from: https://www.unaids.org/en/regionscountries/countries/ethiopia. Accessed November 6, 2020.
   Google Scholar
• Health NIo. What is HAART? | National Institute on Drug Abuse (NIDA); 2020. Available from: https://www.drugabuse.gov/publications/research-reports/hivaids/what-haart. Accessed November 5, 2020.
   Google Scholar
• CDC. HIV treatment; 2020. Available from: https://www.cdc.gov/hiv/basics/livingwithhiv/treatment.html. Accessed May 12, 2021.
   Google Scholar
• World Health Organization. Guideline on when to start antiretroviral therapy on pre-exposure prophylaxis for HIV; 2015. Available from: https://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/. Accessed June 1, 2021.
   Google Scholar
• Glass TR, Motaboli L, Nsakala B, et al. The viral load monitoring cascade in a resource-limited setting: a prospective multicentre cohort study after introduction of routine viral load monitoring in rural Lesotho. PLoS One. 2019;14(8):e0220337. doi:10.1371/journal.pone.0220337
   PubMed Web of Science ®Google Scholar
• Lecher S, Williams J, Fonjungo PN, et al. Progress with scale-up of HIV viral load monitoring—seven sub-Saharan African countries, January 2015–June 2016. Morbid Mortal Wkly Rep. 2016;65(47):1332–1335. doi:10.15585/mmwr.mm6547a2
   PubMed Web of Science ®Google Scholar
• Roberts T, Cohn J, Bonner K, Hargreaves S. Scale-up of routine viral load testing in resource-poor settings: current and future implementation challenges. Clin Infect Dis. 2016;62(8):1043–1048. doi:10.1093/cid/ciw001
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, July 2017. 2017.
   Google Scholar
• Foundation EGPA. Advanced HIV disease and opportunistic infection; 2021. Available from: https://www.pedaids.org/our-expertise/advanced-hiv-disease-and-opportunistic-infection/. Accessed June 1, 2021.
   Google Scholar
• SinoBiological. Cluster of differentiation 4/CD4. 2021. Available from: https://www.sinobiological.com/research/cd-antigens/cluster-of-differentiation-4. Accessed May 15, 2021.
   Google Scholar
• No A. What’s new in treatment monitoring: viral load and CD4 testing. Update. 2017.
   Google Scholar
• Ford N, Meintjes G, Pozniak A, et al. The future role of CD4 cell count for monitoring antiretroviral therapy. Lancet Infect Dis. 2015;15(2):241–247. doi:10.1016/S1473-3099(14)70896-5
   PubMed Web of Science ®Google Scholar
• Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(9):1308–1311. doi:10.1093/cid/ciu094
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and Children. World Health Organization; 2007.
   Google Scholar
• Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008;13:25.
   PubMed Web of Science ®Google Scholar
• Ayele G, Tessema B, Amsalu A, Ferede G, Yismaw G. Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia. BMC Immunol. 2018;19(1):37. doi:10.1186/s12865-018-0278-4
   PubMed Web of Science ®Google Scholar
• Manaye GA, Abateneh DD, Kebede KM, Belay AS. Immunological response during HAART and determinants of current CD4+ T-cell count among HIV/AIDS patients attending University of Gondar Referral Hospital, Northwest Ethiopia. HIV/AIDS (Auckland, NZ). 2020;12:295.
   Google Scholar
• Gezie LD. Predictors of CD4 count over time among HIV patients initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia: multilevel analysis. BMC Res Notes. 2016;9(1):1–9. doi:10.1186/s13104-016-2182-4
   Google Scholar
• Desta AA, Wubayehu Woldearegay T, Berhe AA, Futwi N, Gebremedhn Gebru G, Godefay H. Immunological recovery, failure and factors associated with CD-4 T-cells progression over time, among adolescents and adults living with HIV on antiretroviral therapy in northern Ethiopia: a retrospective cross sectional study. PLoS One. 2019;14(12):e0226293. doi:10.1371/journal.pone.0226293
   Web of Science ®Google Scholar
• Ebonyi AO, Agbaji OO, Anejo-Okopi JA, et al. Factors associated with a low CD4 count among HIV-1 infected patients at enrolment into HAART in Jos, Nigeria. Br J Med Med Res. 2014;4(13):2536–2545. doi:10.9734/BJMMR/2014/8469
   Google Scholar
• Smith CJ, Sabin CA, Youle MS, et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis. 2004;190(10):1860–1868. doi:10.1086/425075
   PubMed Web of Science ®Google Scholar
• Florence E, Lundgren J, Dreezen C, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med. 2003;4(3):255–262. doi:10.1046/j.1468-1293.2003.00156.x
   PubMedGoogle Scholar
• Farhadian M, Mohammadi Y, Mirzaei M, Shirmohammadi-Khorram N. Factors related to baseline CD4 cell counts in HIV/AIDS patients: comparison of poisson, generalized poisson and negative binomial regression models. BMC Res Notes. 2021;14(1):1–7. doi:10.1186/s13104-021-05523-w
   PubMed Web of Science ®Google Scholar
• Montarroyos UR, Miranda-Filho DB, César CC, et al. Factors related to changes in CD4+ T-cell counts over time in patients living with HIV/AIDS: a multilevel analysis. PLoS One. 2014;9(2):e84276. doi:10.1371/journal.pone.0084276
   PubMed Web of Science ®Google Scholar
• Akinbami AA, Gbadegesin A, Ajibola SO, et al. Factors influencing CD4 cell count in HIV-positive pregnant women in a secondary health center in Lagos, Nigeria. HIV/AIDS (Auckland, NZ). 2015;7:115.
   Google Scholar
• Bruneau L, Billaud E, Raffi F, Hanf M. Factors associated with the level of CD4 cell counts at HIV diagnosis in a French cohort: a quantile regression approach. Int J STD AIDS. 2017;28(4):397–403. doi:10.1177/0956462416650980
   Web of Science ®Google Scholar
• Seyoum A, Zewotir T, Zewotir T. Quasi-poisson versus negative binomial regression models in identifying factors affecting initial CD4 cell count change due to antiretroviral therapy administered to HIV-positive adults in North–West Ethiopia (Amhara region). AIDS Res Ther. 2016;13(1):1–10. doi:10.1186/s12981-016-0119-6
   Web of Science ®Google Scholar
• Helleberg M, Kronborg G, Larsen CS, et al. CD4 decline is associated with increased risk of cardiovascular disease, cancer, and death in virally suppressed patients with HIV. Clin Infect Dis. 2013;57(2):314–321. doi:10.1093/cid/cit232
   PubMed Web of Science ®Google Scholar
• CSA. Population and housing census 2007 report, SNNPR, part I: population size and characteristics; 2007 Available from: https://microdata.worldbank.org/index.php/catalog/2747/related-materials. Accessed March 21, 2021.
   Google Scholar
• NACO. National guidelines on second-line ART for adults and adolescents. 2013. Available from: http://naco.gov.in/sites/default/files/National%20Guidelines%20on%20Second-line%20and%20Alternative%20First-line%20ART%20For%20Adults%20and%20Adolescents%20May%202013_0.pdf. Accessed June 1, 2021.
   Google Scholar
• World Health Organization. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2014.
   Google Scholar
• Delhi N. Department of AIDS control, national AIDS control organisation, ministry of health and family welfare, Government of India; 2012. Curr Epidemiol Situation HIV/AIDS Ann Rep. 2011;12.
   Google Scholar
• Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS (London, England). 2009;23(6):697. doi:10.1097/QAD.0b013e3283262a78
   PubMed Web of Science ®Google Scholar
• Ayalew MB, Kumilachew D, Belay A, et al. First-line antiretroviral treatment failure and associated factors in HIV patients at the University of Gondar Teaching Hospital, Gondar, Northwest Ethiopia. HIV/AIDS (Auckland, NZ). 2016;8:141.
   PubMedGoogle Scholar
• Bokretsion GB, Endalkachew N, Getachew KA. HIV/AIDS treatment failure and its determinant factors among first line HAART patients at Felege-Hiwot Referral Hospital, Bahir Dar, Northwest Ethiopia. J AIDS Clin Res. 2017;8(11).
   Google Scholar
• Matthews LT, Crankshaw T, Giddy J, et al. Reproductive decision-making and periconception practices among HIV-positive men and women attending HIV services in Durban, South Africa. AIDS Behav. 2013;17(2):461–470. doi:10.1007/s10461-011-0068-y
   PubMed Web of Science ®Google Scholar
• Kaida A, Laher F, Strathdee SA, et al. Childbearing intentions of HIV-positive women of reproductive age in Soweto, South Africa: the influence of expanding access to HAART in an HIV hyperendemic setting. Am J Public Health. 2011;101(2):350–358. doi:10.2105/AJPH.2009.177469
   PubMed Web of Science ®Google Scholar
• Kisakye P, Akena WO, Kaye DK. Pregnancy decisions among HIV-positive pregnant women in Mulago Hospital, Uganda. Cult Health Sex. 2010;12(4):445–454. doi:10.1080/13691051003628922
   PubMed Web of Science ®Google Scholar
• King R, Khana K, Nakayiwa S, et al. ‘Pregnancy comes accidentally-like it did with me’: reproductive decisions among women on ART and their partners in rural Uganda. BMC Public Health. 2011;11(1):530. doi:10.1186/1471-2458-11-530
   Web of Science ®Google Scholar
• El-Khatib Z, Katzenstein D, Marrone G, et al. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011;6(3):e17518. doi:10.1371/journal.pone.0017518
   PubMed Web of Science ®Google Scholar
• Jaka H, Mshana S, Liwa A, Peck R, Kalluvya S. Prevalence of immunological failure and durability of first line antiretroviral therapy at Bugando Hospital Mwanza, Tanzania. Tanzan Med J. 2009;24(2).
   Google Scholar
• Bacha T, Tilahun B, Worku A. Predictors of treatment failure and time to detection and switching in HIV-infected Ethiopian children receiving first line anti-retroviral therapy. BMC Infect Dis. 2012;12(1):1–8. doi:10.1186/1471-2334-12-197
   PubMed Web of Science ®Google Scholar
• Assefa A, Gelaw B, Getnet G, Yitayew G. The effect of incident tuberculosis on immunological response of HIV patients on highly active anti-retroviral therapy at the university of Gondar hospital, northwest Ethiopia: a retrospective follow-up study. BMC Infect Dis. 2014;14(1):1–8. doi:10.1186/1471-2334-14-468
   Web of Science ®Google Scholar
• Dessie ZG, Zewotir T, Mwambi H, North D. Modelling of viral load dynamics and CD4 cell count progression in an antiretroviral naive cohort: using a joint linear mixed and multistate Markov model. BMC Infect Dis. 2020;20:1–14. doi:10.1186/s12879-020-04972-1
   Web of Science ®Google Scholar
• Maurya S, Singh R, Negi N, Kapil A, Chaudhry R, Das B. The level of education affects CD4 cell count and wellness among HIV infected adult between age group 18 to 60 years. Int J Infect Dis. 2016;45:264. doi:10.1016/j.ijid.2016.02.589
   Web of Science ®Google Scholar
• Weinberg JL, Kovarik CL. The WHO clinical staging system for HIV/AIDS. AMA J Ethics. 2010;12(3):202–206.
   Google Scholar
• Kagaayi J, Makumbi F, Nakigozi G, et al. WHO HIV clinical staging or CD4 cell counts for antiretroviral therapy eligibility assessment? An evaluation in rural Rakai district, Uganda. Aids. 2007;21(9):1208–1210. doi:10.1097/QAD.0b013e32810c8dce
   Web of Science ®Google Scholar
• Sorsa A. Clinical, immunological and virological responses of zidovudine-lamivudine-nevirapine versus zidovudine-lamivudine-efavirenz antiretroviral treatment (ART) among HIV-1 infected children: Asella Teaching and Referral Hospital, South-East Ethiopia. Open Med Inform J. 2018;12:11. doi:10.2174/1874431101812010011
   Google Scholar
• Desta AA, Kidane KM, Bahta YW, et al. Determinants of immunological recovery following HAART among severely immunosuppressed patients at enrolment to care in Northern Ethiopia: a retrospective study. BMJ Open. 2020;10(8):e038741. doi:10.1136/bmjopen-2020-038741
   Web of Science ®Google Scholar
• Ojha CR, Shakya G, Dumre SP. Virological and immunological status of the people living with HIV/AIDS undergoing ART treatment in Nepal. Biomed Res Int. 2016;2016:1–7. doi:10.1155/2016/6817325
   Web of Science ®Google Scholar
• Waters L, Stebbing J, Jones R, et al. A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts. J Antimicrob Chemother. 2004;54(2):503–507. doi:10.1093/jac/dkh329
   Web of Science ®Google Scholar
• Wang H, Zhou J, He G, et al. Consistent ART adherence is associated with improved quality of Life, CD4 counts, and reduced hospital costs in central China. AIDS Res Hum Retroviruses. 2009;25(8):757–763. doi:10.1089/aid.2008.0173
   PubMed Web of Science ®Google Scholar
• Abrogoua DP, Kablan BJ, Kamenan BAT, Aulagner G, N’Guessan K, Zohoré C. Assessment of the impact of adherence and other predictors during HAART on various CD4 cell responses in resource-limited settings. Patient Prefer Adherence. 2012;6:227. doi:10.2147/PPA.S26507
   PubMed Web of Science ®Google Scholar
• Molla AA, Gelagay AA, Mekonnen HS, Teshome DF. Adherence to antiretroviral therapy and associated factors among HIV positive adults attending care and treatment in University of Gondar Referral Hospital, Northwest Ethiopia. BMC Infect Dis. 2018;18(1):266. doi:10.1186/s12879-018-3176-8
   Web of Science ®Google Scholar
• Williams PL, Storm D, Montepiedra G, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics. 2006;118(6):e1745–e1757. doi:10.1542/peds.2006-0493
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Easley KA, Orav EJ, et al. Cardiac dysfunction and mortality in HIV-infected children: the prospective P2C2 HIV multicenter study. Circulation. 2000;102(13):1542–1548. doi:10.1161/01.CIR.102.13.1542
   Web of Science ®Google Scholar
• Sudano I, Spieker LE, Noll G, Corti R, Weber R, Lüscher TF. Cardiovascular disease in HIV infection. Am Heart J. 2006;151(6):1147–1155. doi:10.1016/j.ahj.2005.07.030
   PubMed Web of Science ®Google Scholar
• Buba F. Cardiovascular opportunistic infections in HIV disease. 2011.
   Google Scholar
• Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight). HIV Med. 2014;15:1–85. doi:10.1111/hiv.12119
   Web of Science ®Google Scholar
• Okoye AA, Picker LJ. CD 4+ T‐cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev. 2013;254(1):54–64. doi:10.1111/imr.12066
   PubMed Web of Science ®Google Scholar
• Carter M. Any reduction in viral load has immunologic benefits for people with HIV who have triple-class treatment failure; 2013. Available from: https://www.aidsmap.com/news/jan-2013/any-reduction-viral-load-has-immunologic-benefits-people-hiv-who-have-triple-class. Accessed November 23, 2020.
   Google Scholar
• Fokam J, Billong SC, Jogue F, et al. Immuno-virological response and associated factors amongst HIV-1 vertically infected adolescents in Yaoundé-Cameroon. PLoS One. 2017;12(11):e0187566. doi:10.1371/journal.pone.0187566
   PubMed Web of Science ®Google Scholar
• Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340(21):1605–1613. doi:10.1056/NEJM199905273402101
   PubMed Web of Science ®Google Scholar
• Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5(5):512–517. doi:10.1038/8394
   PubMed Web of Science ®Google Scholar
• Kokeb M, Degu G. Immunological response of HIV-infected children to highly active antiretoviral therapy at Gondar university hospital, north-western Ethiopia. Ethiop J Health Sci. 2016;26(1):25–30. doi:10.4314/ejhs.v26i1.6
   Google Scholar